- Home
- ULCC vs REPL Comparison
ULCC vs REPL Comparison
Compare ULCC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- REPL
- Stock Information
- Founded
- ULCC 1994
- REPL 2015
- Country
- ULCC United States
- REPL United States
- Employees
- ULCC N/A
- REPL N/A
- Industry
- ULCC Air Freight/Delivery Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- REPL Health Care
- Exchange
- ULCC Nasdaq
- REPL Nasdaq
- Market Cap
- ULCC 719.5M
- REPL 757.8M
- IPO Year
- ULCC 2021
- REPL 2018
- Fundamental
- Price
- ULCC $4.16
- REPL $12.62
- Analyst Decision
- ULCC Hold
- REPL Strong Buy
- Analyst Count
- ULCC 11
- REPL 7
- Target Price
- ULCC $5.22
- REPL $21.00
- AVG Volume (30 Days)
- ULCC 3.6M
- REPL 1.8M
- Earning Date
- ULCC 08-07-2025
- REPL 08-07-2025
- Dividend Yield
- ULCC N/A
- REPL N/A
- EPS Growth
- ULCC N/A
- REPL N/A
- EPS
- ULCC 0.30
- REPL N/A
- Revenue
- ULCC $3,822,000,000.00
- REPL N/A
- Revenue This Year
- ULCC $4.64
- REPL N/A
- Revenue Next Year
- ULCC $12.84
- REPL N/A
- P/E Ratio
- ULCC $14.03
- REPL N/A
- Revenue Growth
- ULCC 5.99
- REPL N/A
- 52 Week Low
- ULCC $2.79
- REPL $6.44
- 52 Week High
- ULCC $10.26
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ULCC 57.35
- REPL 78.20
- Support Level
- ULCC $4.03
- REPL $9.26
- Resistance Level
- ULCC $4.22
- REPL $9.90
- Average True Range (ATR)
- ULCC 0.22
- REPL 0.64
- MACD
- ULCC 0.04
- REPL 0.32
- Stochastic Oscillator
- ULCC 61.46
- REPL 89.31
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.